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Objective: The incidence of cognitive impairment is increasing with age; however, little is
known about the role of hyperglycemia in cognitive impairment. This study focuses on
investigating the relationship between diabetes mellitus type 2 and cognitive impairment.
Methods: 60 diabetic patients, amongst whom, 30 had a well-controlled diabetes status and
the other 30 had not. These patients were compared to 60 non-diabetic controls whose age,
sex and educational class matched with the individuals of the first group. Patients with
important risk factors for cognitive disorders (renal failure, major depressive disorders and
psychoactive drug users, cerebrovascular accident history, etc.) were not included in the
study. Modified Mini Mental Status examination (mMMSE) was done for all patients by a
blinded expert examiner.
Results: Subjects with diabetes (n = 60) had lower MMSE score than those without diabetes
(P < .01). Diabetes was also associated with increased odds of cognitive decline as deter-
mined by MMSE scores (odds ratio = 1.9; CI = 95%, 1.01–3.6). A significant correlation
between duration of disease and cognitive dysfunction was observed, P = 0.001. Also, the
same correlation was found for quality of diabetes control, P = 0.002.
Conclusion: Diabetes mellitus is associated with lower levels of cognitive function.
# 2008 Elsevier Ireland Ltd. All rights reserved.
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The worldwide incidence and prevalence of diabetes mellitus
(DM) is increasing, due almost exclusively to an increase in
non-insulin dependent (type 2) DM, which represents more
than 90% of all cases of diabetes. Presently, there is a global
pandemic of type 2 DM and its clinical sequel [1].
Diabetes mellitus not only causes somatic complications
but also may result in accelerated cognitive dysfunction.
Dementia and cognitive decline are among the most
common and most feared conditions of old age, making the
identification of modifiable risk factors for dementia, an
urgent public health priority [2].* Corresponding author.
E-mail address: arami_ma@yahoo.com (M.A. Arami).
0168-8227/$ – see front matter # 2008 Elsevier Ireland Ltd. All rights
doi:10.1016/j.diabres.2008.08.020A recent study with the purpose of verifying whether
borderline diabetes may increase the risk of dementia and
(Alzheimer’s disease) AD, has been carried out on 1173
dementia- and diabetes-free individuals of age 75 or over.
Subjects were examined longitudinally, for three times in
order to identify the ones with dementia and AD. Borderline
diabetes was defined as a random plasma glucose level of 7.8–
11.0 mmol/L. During a 9-year follow-up, 397 subjects devel-
oped dementia, including 307 Alzheimer’s cases. At the
baseline, 47 subjects were identified with borderline diabetes.
Borderline diabetes was associated with adjusted hazard
ratios (95% CIs) of 1.67 (1.04–2.67) for dementia and 1.77 (1.06–
2.97) for AD. Finally, the researchers come up with thisreserved.
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dementia and Alzheimer’s disease and the risk effect is
independent of the future development of diabetes [3].
There is a growing interest in preclinical transitional states
of AD as targets for treatment and prevention. Mild cognitive
impairment (MCI), and particularly amnestic MCI, has been
described as a transitional state between normal cognition
and AD that is increasingly used in clinical and research
settings [4].
Extensive research on the effects of diabetes on cognitive
function in old age has providedmixed findings. Although the
majority of the studies have found negative effects on
cognitive functioning related to diabetes, several studies have
reported no relationship [5].
In a cross-sectional study of citizens, aged 75, 80, or 85
years, Croxson et al. obtained a mental status examination
and an oral glucose tolerance test on 239 individuals. Among
the 31 patients, the proportionwith low cognitive function did
not differ significantly from that for normal individuals [6]. By
contrast, Katzman et al. reported a significant association
between self-reported diabetes anddementia in a case-control
study of 434 healthy volunteers aged 75–85 years followed over
a 5-year period [7].
Iran is also a country with high prevalence of diabetes
mellitus, but investigation of the relationship between
diabetes mellitus and cognitive impairment has not been
reported. The aim of this investigation is to reveal the
relationship between diabetes mellitus type 2 and cognitive
impairment by a cross-sectional population based study.2. Materials and methods
Our study is a cross-sectional one and started in January 2005
in Shahid Beheshty General Hospital and Golabchi Diabetes
Center, Kashan, Iran.
After reviewing patients’ medical records, we selected type
2 diabetics according to American Diabetes Association
criteria for diagnosis of diabetes mellitus , fasting plasma
glucose (FPG) at or above 126 mg/dL (7.0 mmol/L), a 2-h value in
an oral glucose tolerance test (OGTT) at or above 200 mg/dL
(11.1 mmol/L), or a random (or ‘‘casual’’) plasma glucose
concentration 200 mg/dL (11.1 mmol/L) in the presence of
symptoms and the diagnosis of diabetesmust be confirmedon
a subsequent day by measuring any one of the three criteria
[8]. To determine type 2 DM, patients must have been
diagnosed in the 3rd or later decades of their life and had
no history of diabetic ketoacidosis.
Diabetic patients were under treatment with oral hypogly-
cemic agents, glyburid and metformin in various dosages and
other non-pharmacologic strategies have been used by most
cases including diet control and physical exercise.
Education-wise, we divided the individuals into three
classes, according to the number of years which they had
attended school. Classes are: low class (<5 years), middle class
(5–12 years) and high class (>12 years).
All cases with cognitive dysfunction caused by reasons
other than hyperglycemia were excluded from study. How-
ever, patients who have been under treatment with psy-
choactive/depressant drugs (anticholinergics, narcotics,antidepressants, benzodiazepines, or major tranquilizers),
any cerebrovascular accident history and presence of major
depressive symptoms were excluded. Complicated hyperten-
sions (cerebrovascular accidents, multiinfarct dementias,
renal failure, etc.) or patients with uncontrolled prolonged
hypertension were also excluded from our study.
Type 2 DM emerges several years before the diagnosis. For
this,wedefined ‘‘Diseaseduration’’ tobe the timespanbetween
diagnosis of diabetes mellitus and the MMSE examination.
Based on glycemic measures in regular follow-up exam-
inations in the latter months of this study, diabetic patients
were divided into two groups, ‘‘well-controlled’’: FPG less than
120 mg/dL and 2 h post prandial plasma glucose less than
180 mg/dL and hemoglobin A1c  7%), and ‘‘poorly con-
trolled’’: hemoglobin A1c  9%.
Fromeach group (well-controlled and poorly controlled), 30
patients were selected consecutively, making up a total of 60
diabetic patients. As control, 60 non-diabetics were selected
from individuals, referred to our clinic for other reasons like
periodic medical check-up, screening for DM, control of
hypertension and etc. All of them were evaluated for DM by
FPG and OGTT and like DM patients; cases which had any
causes with any cognitive impairment were excluded. Selec-
tion for control group was also done consecutively and their
age, sex and education levels conform to those of diabetic
cases.
Then each one from case and control group evaluated for
cognitivefunctionbyaneurologistexpert inthefieldofdementia
and was blinded to subjects of study groups. The instrument
used,was themodifiedMiniMental Status Examination (MMSE)
Questionnaire. This test was introduced as a standardmeasure
of cognitive function to be used for both research and clinical
purposes.Ascoreof lessthan24consideredtobeconsistentwith
acognitive impairment/dementia [9]. Scoresof20–23considered
as to have mild cognitive impairment, 10–19 moderate and 0–9
severe impairment.3. Statistical analysis
The Chi-square test was applied to test differences in
proportions of qualitative variables and continuous variables
were analyzed using Student’s t-test, with 5% level of
significance.
Mean score of MMSE compared between control and case
groups, using Student’s t-test (two sample equal variance and
two tailed distributions). Also, this score compared between
well-controlled and poorly controlled DM patients using the
same test. Using Chi-square test, groups were compared for
evidence of cognitive impairment and its severity as well as
the association between cognition and DM control quality.
Logistic regression was applied to find the relationship
between some characteristics of diabetes mellitus and
cognitive impairment.4. Results
A total of 120 caseswere studied, 60 type 2 DMpatients as case
group and 60 non-diabetics as control with mean age of
Table 2 – Characteristics of good controlled and poor
controlled diabetics and comparison of cognitive state in
both
Good control
(number = 30)
Poor control
(number = 30)
P value
Sex P = ns
Male 16 (53%) 16 (53%)
Female 14 (47%) 14 (47%)
Age (mean, years) 50.4  8.31 48.7  8.41 P = 0.43
Educational states P = ns
Low level 8 (26.3%) 8 (26.3%)
Medium level 20 (66.3%) 20 (66.3%)
High level 2 (6.3%) 2 (6.3%)
Cognitive
impairment
Yes 8 (24.3%) 13 (40%)
No 22 (75.7%) 17 (60%) P = 0.176
MMSE score 27.07  2.71 25.07  2.1 P = 0.002
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male and 28 (46.7%) female in DM group and 34 (56.7%) male
and 26 (43.3) female in control non-DM group (P = 0.71). Mean
age was 49.5  8.3 years in DM group and 50.18  7.52 years in
non-DMgroup (P = 0.67).Meanduration of disease inDMgroup
was 8.45  3 years.
Serum HbA1c level was high in all poorly controlled cases.
Also, their blood glucose, both in fasting and random checks,
was high. Mean serum HbA1c was 6.09  0.53 for the well-
controlled group and 10.26  0.59 for poorly controlled group.
Twenty (33.3%) diabetic patients and 15 (25%) control
subjects suffered from hypertension (d.f. = 1, p < 0.31). Educa-
tional status of subjects is as follows: in diabetics 16 (26.7%)
cases were in low level, 40 (66.7%) diabetics were in medium
level and 4 (6.7%) cases had higher educations. These were 14
(23.3%), 39 (65%) and 7 (11.7%) respectively in control group
(P = 0.62).
Disease durationwas significantly longer in patientswhose
DM control was not adequate. Mean duration of disease was
6.9  2.7 years for patients with good control and 10  2.66
years in poorly controlled diabetics (CI = 95%, 1.7 to 4.5,
p < 0.0001).
From 60 diabetics, 21 (35%) cases had cognitive impairment
(i.e. MMSE score of less than 24). In non-diabetics, cognitive
impairment was detected only in 11 (18.3%) out of 60 cases
which is significantly lower than the frequency of cognition
impairment in DM group (p = 0.038, CI = 95%, 1.01 < OR =
1.9 < 3.6).
Mean of MMSE scores of subjects was 27.16  2.72 (range
20–30). This score was 28.25  2.38 for non-diabetics and
26.07  2.6 for diabetics. Statistical analysis showed a sig-
nificant difference between MMSE score of two groups
(P = 0.001). Cognitive impairment was in mild level in both
groups and there were no moderate or severe cases (Table 1).
As stated earlier, there were two subgroups within the
diabetics, namely, the ones with well-controlled DM and the
ones with poorly controlled DM and both matched in age, sexTable 1 – Characteristics of diabetic and non-diabetic
group and comparison of cognitive state in both
Diabetes
(number
= 60)
Non-diabetes
(number
= 60)
P value
Sex P = 0.71
Male 32 (53.3%) 34 (56.7%)
Female 28 (46.7%) 26 (43.3)
Age (mean, years) 49.5  8.3 50.18  7.52 P = 0.67
Education state P = 0.62
Low level 16 (26.7%) 14 (23.3%)
Medium level 40 (66.7%) 39 (65%)
High level 4 (6.7%) 7 (11.7%)
Cognitive impairment P = 0.038
Yes 21 (35%) 11 (18.3%)
No 39 (65%) 49 (81.7%)
Mild 19 (31.6%) 10 (16.7%)
Moderate 2 (3.33%) 1 (1.67%)
Severe 0 0
MMSE score 26.07  2.6 28.25  2.38 P = 0.001 Fig. 1 – Correlation between disease duration and MMS
score.and education. Mean score of MMSE was 27.07  2.71 in well-
controlled and 25.07  2.1 in poorly controlled patients
(P = 0.002). This shows a significant MMSE score difference
in well-controlled and poorly controlled DM. However, in
comparing these two groups for presence of cognitive
impairment, there was not significant evidence of a difference
between poorly controlled and well-controlled DM as: in
poorly controlled and well-controlled groups, 13 (40%) and 8
(24.3%) patients suffered from cognitive impairment and 17
(60%) and 22 (75.7%) did not, respectively (P = 0.176) (Table 2).
Twenty-one (35%) diabeticswith cognitive impairment had
mean disease duration of 9.9  2.9 years and 39 (65%) patients
without cognitive impairment had mean disease duration of
7.64  2.78 years. Statistical analysis shows that there is a
significant difference in the disease duration for diabetic
patients with or without cognitive impairment. It is evident
that the disease duration is remarkably longer in patientswith
cognitive impairments than the ones without such disorders
(P = 0.004). Also Pearson’s correlation coefficient shows nega-
tive correlation between disease duration and cognitive
impairment (R = 0.408, P = 0.001) (Fig. 1).
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Controversial results have been reported about the status of
diabetes mellitus as a risk for mental impairment.
To determinewhether diabetes is related to a higher risk of
mild cognitive impairment, during a longitudinal cohort
study, Luchsinger et al., studied 918 of 1772 participants
without prevalent MCI or dementia at baseline and with at
least 1 follow-up interval. Diabetes was related to a signifi-
cantly higher risk of all-cause MCI and amnestic MCI after
adjustment for all covariates. Diabetes was also related to a
higher risk of non-amnestic MCI, but this association was
appreciably attenuated after adjustment for socioeconomic
variables and vascular risk factors [4].
In our study, regardless of a small number of participants
and a different method and scale in determination of MCI, yet
we found a higher prevalence of MCI in diabetic group.
Allen et al. arranged a literature search and evaluated 10
studies (nine population-based and one of case-controlled
design) that included a definable diabetic population and
assessments of cognitive function at baseline and at follow-
up. These 10 studies utilized a combination of domain-specific
cognitive assessments and a clinical diagnosis of dementia in
the assessment of cognitive function. Diabetes was associated
with either an accelerated cognitive decline or an increased
incidence of dementia in eight over nine of the population-
based studies [10].
Yaffe et al. investigated the association between diabetes
and impaired fasting glucose and cognition and risk of
developing both dementia and mild cognitive impairment in
older women. They analyzed data from a 4-year randomized
trial of raloxifene among 7027 women at 178 sites. The main
outcome was baseline and 4-year change on standardized
cognitive tests and risk of developing clinically significant
cognitive impairment. There was greater 4-year decline
among diabetics (P = 0.001), and further adjustment for
education, race, and depression led to similar results [11].
Similarly, in a cross-sectional study of 462 men aged 69–89
years, diabetic individuals scored significantly lower on the
MMSE than men with normal glucose tolerance; among non-
diabetic individuals, those with higher insulin levels made
more errors than those with lower levels [12].
However, similar results have not been found in some
studies. There was no relationship between type 2 diabetes
and cognitive function in the Rancho Bernardo cohort study
which measured by 10 tests [13]. Considering our findings
regarding theduration of diabetes, one explanationmaybe the
predominance of recently diagnosed diabetes in that cohort:
most of their participants had diabetes for 3 years whereas the
mean duration of disease of our diabetics was 8.45 years.
Our conclusion that, longer duration of disease seems to be
related to cognitive dysfunction is consistent with other
studies. Gregg et al. showed increasing risk of cognitive decline
with increasing duration of diabetes [14]. Also, it was showed
that each 5-year increment between diabetes diagnosis and
cognitive assessment was associated with lower scores on
tests of logical memory, word fluency, and similarities [15].
Small treatment studies have found that administration of
oral hypoglycemic agents to non-demented patients with type
2 diabetes resulted in improved performance on cognitivetasks [16]. Interestingly, in the study of osteoporotic fractures
[14] and the Framingham study [15], insulin treatment was
related to poorer cognitive performance, and in the Framing-
ham study, diabetic patients treated with oral medications or
diet performed similarly to non-diabetic patients. Unfortu-
nately, we did not have enough patients using insulin to
compare oral hypoglycemic agents and insulin effects on
cognitive function but in overall we found a significant
correlation between quality of diabetes control and cognitive
dysfunction (P = 0.002, Table 2).
Recently, Ryan et al. evaluated the effects of improvements
in metabolic control on the cognitive dysfunction associated
with type 2 diabetes. Their randomized double-blind trial
enrolled 145 subjects at 18 centers in the United States.
Cognitive functionwas assessed at baseline andweek 24 using
the Digit Symbol Substitution Test, the Rey Auditory Verbal
Learning Test, and the Cambridge Neuropsychological Test
Automated Battery. Working memory improved with both
rosiglitazone (P < 0.001) and glyburide (P = 0.017). Cognitive
improvement was significantly correlated with improved
glycemic control as measured by FPG. They concluded that
the magnitude of cognition improvement is correlated with
the degree to which FPG improved. According to their results a
cognitive benefit is achievable with pharmacological inter-
ventions targeting glycemic control [17].
Based on our study, onemight conclude that type 2 diabetes
is related to poor performance on cognitive function and good
control of disease seemed to lower this disability and this could
result to poorer ability in diabetes self-care and greater
dependency. For above mentioned reasons, routine screening
of cognition in diabetics is recommended. Because both
diabetes and poor cognitive function are common conditions
especially among elderly individuals, further investigations are
warranted for clear understanding of subject.6. Conclusion
In the present study we evaluated the effect of diabetes
mellitus on Cognitive impairment. We compared prevalence
of cognitive impairment in diabetic and non-diabetic group,
matched in age, sex and educational state. According to our
findings, cognitive impairment was mild in both groups and
prevalence was nearly two times in diabetic patients. In
diabetic group, poor controlled DM had a lower MMSE scores
than good controlled DM. There was a negative relationship
between duration of disease and MMSE scores but not in
prevalence of cognitive impairment.Conflict of interest
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